First AI breast cancer diagnosis technology was approved by UK and EU!
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
First AI breast cancer diagnosis technology was approved by UK and EU!
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Another major development: First AI breast cancer diagnosis technology was approved by UK and EU!
Last month, the U.S. FDA granted the marketing authorization of Paige Prostate, an AI diagnostic system for prostate pathology (>>Review details). This is currently the first and only FDA-approved AI software for pathological diagnosis of prostate biopsy sections.
Recently, AI pathological diagnosis has ushered in significant progress: a new detection technology based on artificial intelligence technology that can predict the most effective treatment method from conventional cancer sample images has been approved for clinical use in health services by the United Kingdom and the European Union.
This advanced technology called PANProfiler is the brainchild of Panakeia’s co-founder and former cancer researcher Pahini Pandya at the University of Cambridge and AI researcher Pandu Raharja-Liu. The two pioneers discovered that subtle differences in the appearance of cancer cells can only be detected by computer vision and artificial intelligence analysis, which reveals key information about the status of potential biomarkers and the best treatment options.
Although some AI tools can determine whether breast cancer is present in digital pathology images, PANProfiler is the only technology that can predict the status of biomarkers to provide information for clinical decision-making , which will speed up diagnosis and reduce expensive and time-consuming laboratory tests.
PANProfiler breast detection is based on the drug Herceptin. It analyzes the digital images of H&E stained breast tumor samples that are routinely collected to determine the PR, ER and HER2 status, which helps determine the best form of treatment for the patient.
PANProfiler breast cancer diagnostic tool can provide diagnostic readings of initial H&E images within 15 minutes, and its accuracy is comparable to laboratory testing methods. Traditional testing may take several weeks to complete. Therefore, PANProfiler provides a faster and cheaper alternative than traditional testing, which can save a lot of money for the medical system every year.
In addition, the technology can also help reduce the backlog of cancer diagnosis in laboratories due to the COVID-19 pandemic. PANProfiler is seamlessly integrated into the digital cancer pathology program and is currently being tested in British hospitals and plans to expand to Europe, North America and Asia.
First AI breast cancer diagnosis technology was approved by UK and EU!
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
